Estradiol valerate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Estradiol valerate
- Molecular weight
- 356.51
- Structure (SMILES)
- CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C
- climaval
- Climaval
- deladumone
- Deladumone
- delestrogen
- Delestrogen
- estradiol valerate
- Estradiol valerate
- estradiol valerate component of ditate ds
- Estradiol valerate component of ditate-ds
- estradiol valerate component of natazia
- Estradiol valerate component of natazia
- femtab
- Femtab
- progynon depot
- Progynon depot
- progynon depot 10
- Progynon-depot-10
- progynova
- Progynova
- .beta.-estradiol 17-valerate
- 4 mg oral estradiol valerate
- beta estradiol 17 valerate
- ditate ds component estradiol valerate
- DITATE-DS COMPONENT ESTRADIOL VALERATE
- estra 1 3 5 10 triene 3 17 diol 17 beta 17 pentanoate
- ESTRA-1,3,5(10)-TRIENE-3,17-DIOL(17.BETA.)-, 17-PENTANOATE
- estradiol 17 valerate
- estradiol 17 valerate mi
- Estradiol 17-valerate
- ESTRADIOL 17-VALERATE [MI]
- estradiol valerate
- Estradiol valerate
- Estradiol Valerate
- Estradiol Valerate (EV) (BAY86-4980)
- ESTRADIOL VALERATE [EP MONOGRAPH]
- ESTRADIOL VALERATE [GREEN BOOK]
- estradiol valerate [INN]
- ESTRADIOL VALERATE [JAN]
- ESTRADIOL VALERATE [MART.]
- ESTRADIOL VALERATE [ORANGE BOOK]
- ESTRADIOL VALERATE [USP MONOGRAPH]
- ESTRADIOL VALERATE [USP-RS]
- ESTRADIOL VALERATE [VANDF]
- Estradiol valerate [WHO-DD]
And 24 more, listed on the interactive page.
- CAS registry numbers
- 979-32-8
- ChEMBL ID
- CHEMBL1511
- InChIKey
- RSEPBGGWRJCQGY-RBRWEJTLSA-N
- PubChem compound IDs
- 13791
- RxNorm IDs (RxCUI)
- 24395
- FDA ingredient codes (UNII)
- OKG364O896
- Applicant
- PH HEALTH
- Approval date
- 15 Jul 1954
- Application number
- NDA009402
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- estradiol valerate
- Type
- Synthetic organic
- Drug name stem
- estr-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
Mechanisms of action
- Mechanism
- Estrogen receptor alpha agonist
- Action type
- Agonist
- Target
- Estrogen receptor
- Protein identifier
- P03372
Open Targets mechanisms
- Mechanism
- Estrogen receptor alpha agonist
- Action type
- Agonist
- Target
- Estrogen receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- ESR1
- Protein identifier
- P03372
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Infertility
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Polycystic Ovary Syndrome
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000660
- Subject identifier
- D011085
- Condition
- Primary Ovarian Insufficiency
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004266
- Subject identifier
- D016649
- Condition
- Atrophy
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000096
- Subject identifier
- D001284
- Condition
- Atrophic Vaginitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001271
- Subject identifier
- D059268
- Condition
- Menopause
- Highest recorded phase
- 4
- Condition identifier
- GO:0042697
- Subject identifier
- D008593
- Condition
- Menorrhagia
- Highest recorded phase
- 4
- Condition identifier
- HP:0000132
- Subject identifier
- D008595
- Condition
- Primary Ovarian Insufficiency
- Highest recorded phase
- 4
- Condition identifier
- HP:0008209
- Subject identifier
- D016649
- Condition
- Dysmenorrhea
- Highest recorded phase
- 3
- Condition identifier
- HP:0100607
- Subject identifier
- D004412
- Condition
- Metrorrhagia
- Highest recorded phase
- 3
- Condition identifier
- HP:0100608
- Subject identifier
- D008796
- Condition
- Hypogonadism
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002146
- Subject identifier
- D007006
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000660
- Condition identifier
- EFO_0004266
- Condition identifier
- EFO_0004714
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008560
- Condition identifier
- EFO_0009520
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009520
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009878
- Condition identifier
- EFO_1000096
- Condition identifier
- EFO_1000096
- Highest recorded phase
- 4
- Condition identifier
- EFO_1001271
- Highest recorded phase
- 3
- Condition identifier
- GO_0042697
- Condition identifier
- GO_0042697
- Highest recorded phase
- 4
- Condition identifier
- HP_0000132
- Condition identifier
- HP_0000132
- Highest recorded phase
- 4
- Condition identifier
- HP_0000789
- Highest recorded phase
- 3
- Condition identifier
- HP_0000855
- Condition identifier
- HP_0002315
- Highest recorded phase
- 3
- Condition identifier
- HP_0008209
- Condition identifier
- HP_0008209
- Highest recorded phase
- 4
- Condition identifier
- HP_0100607
- Highest recorded phase
- 3
- Condition identifier
- HP_0100608
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002050
- Condition identifier
- MONDO_0002146
And 8 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- carcinogenicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- carcinogenicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- application site burn
- Reports
- 38
- Reporting signal score
- 105.208
- Event
- application site erythema
- Reports
- 179
- Reporting signal score
- 508.018
- Event
- application site irritation
- Reports
- 125
- Reporting signal score
- 418.705
- Event
- application site pain
- Reports
- 74
- Reporting signal score
- 136.613
- Event
- application site pruritus
- Reports
- 179
- Reporting signal score
- 567.249
- Event
- application site rash
- Reports
- 247
- Reporting signal score
- 930.744
- Event
- application site reaction
- Reports
- 68
- Reporting signal score
- 215.08
- Event
- application site urticaria
- Reports
- 25
- Reporting signal score
- 82.054
- Event
- application site vesicles
- Reports
- 49
- Reporting signal score
- 133.664
- Event
- bipolar disorder
- Reports
- 4
- Reporting signal score
- 13.498
- Event
- blood oestrogen decreased
- Reports
- 39
- Reporting signal score
- 170.801
- Event
- breast cancer
- Reports
- 143
- Reporting signal score
- 197.815
- Event
- breast cancer female
- Reports
- 44
- Reporting signal score
- 86.6085
- Event
- breast cancer in situ
- Reports
- 27
- Reporting signal score
- 79.8034
- Event
- breast cancer stage iv
- Reports
- 2
- Reporting signal score
- 11.3612
- Event
- breast tenderness
- Reports
- 64
- Reporting signal score
- 174.043
- Event
- cataract subcapsular
- Reports
- 4
- Reporting signal score
- 22.2629
- Event
- congenital coronary artery malformation
- Reports
- 2
- Reporting signal score
- 13.0224
- Event
- cystoid macular oedema
- Reports
- 4
- Reporting signal score
- 17.7908
- Event
- device adhesion issue
- Reports
- 74
- Reporting signal score
- 105.838
- Event
- device material issue
- Reports
- 30
- Reporting signal score
- 99.5721
- Event
- diabetes mellitus inadequate control
- Reports
- 4
- Reporting signal score
- 11.0128
- Event
- diabetic retinal oedema
- Reports
- 4
- Reporting signal score
- 22.6508
- Event
- diabetic retinopathy
- Reports
- 4
- Reporting signal score
- 17.8139
- Event
- diarrhoea
- Reports
- 58
- Reporting signal score
- 90.7146
And 44 more, listed on the interactive page.
- NCT00293059
- NCT00307801
- NCT00490308
- NCT02251925
- NCT02845388
- NCT03832894
- NCT05980091
- NCT00816556
- NCT00909857
- NCT01300676
- NCT01933204
- NCT05300841
- Dose
- 10-20mg
- Route
- Intramuscular
- How often
- Every four weeks
- Use deep intramuscular injection into upper outer quadrant of gluteal muscle
- Use small gauge needle (e.g., 20 gauge x 1.5 inch)
- Visual inspection prior to administration
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 46.53
- Calculated partition coefficient (ALogP)
- 5.35
- Calculated partition coefficient (XLogP)
- 6
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 26
- Molecular formula
- C23H32O3
- Monoisotopic mass
- 356.23514488
- Natural product
- Yes
- 0143-9289
- 0143-9290
- 0143-9291
- 0517-0420
- 0517-0440
- 42023-110
- 42023-111
- 70700-273
- 70700-274
- 70700-275
- Recorded assays
- 1,223
- Active assays
- 52
- Confirmatory
- Other
- Screening
- Summary
- Estrogens
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Oral bioavailability
- Median
- 3
- Mean
- 3
- Minimum
- 3
- Maximum
- 3
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (88)
- "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
- A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest
- A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
- Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women
- Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg With Regards to Reference Product
- Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium
- Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium
- Comparative Cycle Control Europe
- Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users
- Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion
- Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis
- Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients
- Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2
- Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.
- Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
- Effect of Estradiol Pretreatment on Antagonist ICSI Cycles
Approved for (3)
- Hypogonadism
- Premature ovarian failure 1
- Primary ovarian failure
In development for (4)
- Dysmenorrhea Phase 3
- Infertility disorder Phase 3
- Polycystic ovary syndrome Early phase 1
- Postmenopausal atrophic vaginitis Phase 3
Other linked conditions (1)
- Female infertility
Targets (1)
- ESR1 Estrogen receptor alpha agonist